Glycosylasparaginase for treatment of cancers or inflammatory diseases
作者： Eira Kelo , Ilkka Mononen
DOI:
关键词:
摘要: The invention concerns a glycosylasparaginase polypeptide with L-asparaginase activity or its precursor for use in the treatment prevention of cancers inflammatory diseases. also novel pharmaceutical composition comprising either i) precursor, ii) an expression vector encompassing nucleic acid sequence encoding
参考文章(3)
Reiff A, Bernstein B, Zastrow M, Sun Bc, Takei S, Durden Dl, Mitsuhada H, Treatment of collagen induced arthritis in DBA/1 mice with L-asparaginase. Clinical and Experimental Rheumatology. ,vol. 19, pp. 639- 646 ,(2001)
V Kaartinen, T Mononen, R Laatikainen, I Mononen, Substrate specificity and reaction mechanism of human glycoasparaginase. The N-glycosidic linkage of various glycoasparagines is cleaved through a reaction mechanism similar to L-asparaginase. Journal of Biological Chemistry. ,vol. 267, pp. 6855- 6858 ,(1992) , 10.1016/S0021-9258(19)50505-1
Päivi Ylikangas, Ilkka Mononen, Serious neutropenia in ALL patients treated with L-asparaginase may be avoided by therapeutic monitoring of the enzyme activity in the circulation. Therapeutic Drug Monitoring. ,vol. 24, pp. 502- 506 ,(2002) , 10.1097/00007691-200208000-00007